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ABSTRACT
The Sleeping Beauty (SB) transposase and its newly
developed hyperactive variant, SB100X, are of incr-
easing interest for genome modification in experi-
mental models and gene therapy. The potential
cytotoxicity of transposases requires careful as-
sessment, considering that residual integration
events of transposase expression vectors delivered
by physicochemical transfection or episomal retro-
viral vectors may lead to permanent transposase
expression and resulting uncontrollable transpos-
ition. Comparing retrovirus-based approaches
for delivery of mRNA, episomal DNA or integrating
DNA, we found that conventional SB transposase,
SB100X and a newly developed codon-optimized
SB100Xo may trigger premitotic arrest and apop-
tosis. Cell stress induced by continued SB over-
expression was self-limiting due to the induction
of cell death, which occurred even in the absence
of a co-transfected transposable element. The cyto-
toxic effects of SB transposase were strictly dose
dependent and heralded by induction of p53 and
c-Jun. Inactivating mutations in SB’s catalytic
domain could not abrogate cytotoxicity, suggesting
a mechanism independent of DNA cleavage activity.
An improved approach of retrovirus particle-
mediated mRNA transfer allowed transient and
dose-controlled expression of SB100X, supported
efficient transposition and prevented cytotoxicity.
Transposase-mediated gene transfer can thus be
tuned to maintain high efficiency in the absence of
overt cell damage.
INTRODUCTION
The Sleeping Beauty (SB) system (1), consisting of a trans-
poson vector with a gene of interest and a trans-acting
transposase, has been developed as a promising alternative
to integrating retrovirus (iRV)-based gene delivery
vehicles (2,3). The recently introduced hyperactive
SB100X transposase greatly improved the prospects for
efficient gene transfer into many cell types that are of
interest for both, basic research and gene therapy (2).
Compared to the first generation conventional SB (cSB),
which was resurrected from a deficient fish transposon (1),
SB100X contains several mutations that collaboratively
increase its transposition activity without major changes
of the transposon’s close-to-random integration pattern.
Provided that suitable transfection methods are available
for a given target cell type, SB100X reaches stable gene
transfer rates that were previously only achieved by
retrovirus-based vectors (2), including the more recent gen-
erations of lentiviral vectors (4).
The SB transposase is typically transiently supplied to
prevent remobilization of integrated transposable elements
within the genome of target cells. Previous studies have
indicated that the expression level of the transposase
requires careful adjustment to avoid overproduction in-
hibition, which may be triggered by the accumulation of
transposase oligomers incapable of DNA binding possibly
due to incorrect folding of the protein (5,6). Improvements
of the delivery systems have thus gained increasing
interest. Various physicochemical transfection methods,
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DNA-based viral vectors or episomal lentiviral vectors
(eLV) deliver DNA transiently. However, physico-
chemical transfection may induce substantial toxicity in
primary cell types that may limit a wider applicability
of SB. Another concern is that DNA transfection, adeno-
viral vectors and eLV have a residual potency of stable
gene transfer which can affect 0.01–3% of the targeted cell
population (7–9). In the context of a transposon system,
this could lead to permanent genomic insertion of a
transposase source, with uncontrollable transposition
and congruent genomic instability. Transfecting in vitro
generated transposase mRNA has been proposed as
an alternative, transient delivery method (10), but it
remained unclear how this approach can be adjusted to
reach homogenous expression levels in the transfected cell
population.
In previous work, we have introduced a retrovirus
particle-mediated approach of mRNA transduction
[named RMT, (11)]. This method exploits the fact that
retroviral particles package two copies of their plus-
stranded, capped and polyadenylated mRNA genome,
which may serve as a translation template in transduced
cells unless it undergoes reverse transcription (RT). RMT
vectors, containing a mutated artificial primer binding site
(aPBS) that does not match any naturally occurring
tRNA, efficiently block RT (12), and instead promote
protein synthesis. A prerequisite for RMT is that the
retroviral mRNA is introduced in a configuration that
supports efficient translation, as shown for gammaretro-
viral vectors (7,11,13). Lentiviral vectors are less well
suited for RMT because their 50 untranslated region is
relatively large with many aberrant reading frames
preceding the site used to introduce the sequences of
interest (4). Demonstrating that the retroviral mRNA
genome is the active principle of RMT, it was shown to
be sensitive to expression of short-hairpin RNAs in the
target cells (7). In comparison with eLV (14), RMT
leads to a more rapid onset, lower level and shorter
duration of expression, and fully avoids residual integra-
tion events (7).
In the present study, we examined the consequences of
three retrovirus-based transposase delivery systems—tran-
sient expression at a relatively low level (RMT), a more
prolonged and more potent, mostly transient DNA-based
expression from integrase-defective episomal gammaretro-
viral and lentiviral vectors (eRV and eLV) and permanent
expression from integrating gammaretroviral vectors
(iRV)—in terms of transposition efficacy and potential
cytotoxic side-effects. To enhance the potency of RMT,
we modified the expression vectors and codon-optimized
the SB100X coding sequence. To examine the specificity of
potential cytotoxic effects and to assess the versatility of
the expression systems, we took the same approaches to
express a codon-optimized version of the site-specific FLP
recombinase [FLPo, (15)]. We demonstrate a previously
unknown cytotoxic effect of high and prolonged SB ex-
pression, associated with induction and phosphorylation
of p53 and c-Jun. Importantly, cytotoxicity could be
avoided by short-term expression of SB, using RMT or
dose-controlled transient transfection.
MATERIALS AND METHODS
Vector design
The construction of all retroviral and non-viral expres-
sion plasmids that were used in this study is explicitly ex-
plained in ‘Material and Methods’ of the Supplementary
Data.
Cell culture and production of retroviral vector
supernatants
HeLa, HeLa Fucci [kindly provided by Dr A. Miyawaki
(16)], 293T, SC-1-based FLP reporter cells (17) and the
analogously generated HT1080 FLP reporter cells were
grown in Dulbecco’s modified Eagle’s medium
(Biochrom, Berlin, Germany) supplemented with 10%
fetal calf serum, 1mM sodium pyruvate (PAA, Coelbe,
Germany) and 1% Penicillin/Streptomycin (PAA).
Murine induced pluripotent stem (IPS) cells expressing
the FLP indicator cassette were cultured on g-irradiated
C3H murine embryonic fibroblasts (MEFs) in mouse em-
bryonic stem (mES) cell medium as recently described
(17). For retroviral vector production, 6 106 293T cells
were seeded into a 10 cm dish and transfected the next
day using the calcium phosphate precipitation method
assisted by 25 mM chloroquine (Sigma Aldrich, Munich,
Germany). For gammaretroviral production, 5 mg iRV,
RMT or RBid vector plasmids were cotransfected with
expression plasmids for MLV-gag-pol (7 mg) or
integration-defective MLV-gag-pol [D184A, (18)] and
the gylycoprotein from vesicular stomatitis virus (VSVg/
pMD.G; 2 mg). The production of non-fluorescently
labeled RMT and iRV vector supernatants was controlled
by additional transfection of 0.5mg non-viral pCMV-
DsRed-Express expression plasmid (BD Biosciences
Clontech, Heidelberg, Germany). Lentiviral vector pro-
duction was carried out using 5 mg lentiviral vector expres-
sion plasmids together with 12 mg lentiviral wild-type
gag-pol (pcDNA3.gp.4xCTE) or lentiviral integrase-
defective gag-pol (pcDNA3.gpD64V.4xCTE, kindly pro-
vided by M. Milsom, DKFZ / HI-STEM, Heidelberg,
Germany) and 5 mg pRSV.Rev (kindly provided by T.
Hope, Northwestern University, Chicago, IL, USA) and
2 mg pMD.G. To increase bidirectional vector titers, 5 mg
Nodamuravirus B2 protein expression plasmid [NovB2,
(18)] was added to the transfection. Supernatants were
harvested 36 and 60 h post-transfection and if necessary
pooled and concentrated via ultracentrifugation over
night at 13 000g and 4C.
Retroviral cell transduction
Either 2.5 104 SC-1-based or 5 104 HT1080-based FLP
indicator cells were seeded per well of a 24-well-plate. The
next day, serial dilutions/MOIs of lentiviral or gamma-
retroviral supernatants were applied to the cells for 8 h.
Transduction was assisted by 4 mg/ml protamine sulfate
(Sigma Aldrich) and centrifugation for 60min at 400g
and 37C. Murine IPS FLP indicator cells were trans-
duced in single cell suspension. In brief, 3 104 murine
IPS cells were harvested feeder-free, resuspended in
300 ml mES cell medium, transferred into a well of a
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24-well-suspension plate and transduced in the presence of
protamine sulfate with iRV.FLPo and RMT.FLPo par-
ticles at an MOI of 40. The cells were centrifuged as
described above, incubated another hour at 37C and
then replated on g-irradiated C3H MEFs.
RMT-based SB transposition assay
One day prior to transduction, 2 105 HeLa cells were
seeded per well of a 12-well-plate and transduced at
the following day with serial dilutions of concentrated
RMT supernatant variants. Twenty-two hours post-
transduction, cells were transfected with 600 ng of plasmid
DNA that harbors the transposable element expression
cassette encoding for EGFP (pSK.IR.SF.EGFP.pA.IR)
using polyethyleneimine (PEI; Polysciences, Eppelheim,
Germany). The percentage of EGFP+ cells were deter-
mined 2 and 21 days post-transfection via flow cytometry
(fluorescence activated cell sorting [FACS]) and the values
were used for calculation of the transposition rates (EGFP+
cells at Day 21 divided by EGFP+ cells at Day 2).
Corresponding iRV-based SB transposase vectors served
as positive controls for transposition. Cells that were only
transfected with the transposable element plasmid served
as control for background integration events.
Northern blot analysis
Using the calcium phosphate transfection method, 293T
cells were cotransfected with 0.5 mg of pCMV-DsRed-
Express (BD Biosciences Clontech), 7 mg of pMoloney-
MLV-gag-pol and 5 mg of conventional or optimized
RMT vector plasmids (pSF91aPBS, pRSF91aPBS or
pRSF91aPBS+PRE) encoding each either cSB, SB100X
or SB100Xo. Thirty-six hours post-transfection, cells
were harvested and their total RNA was prepared using
the RNAzol extraction method (WAK Chemicals,
Steinbach, Germany). Using the standard northern blot
protocol procedures, 10 mg of each RNA sample was
separated at 2V/cm in 1% agarose under denaturing con-
ditions, transferred to a Biodyne B membrane (Pall
Corporation, Dreieich, Germany) and analyzed via radio-
active probing. Specific probes were directed against the
30 SFFV U3 region and 18 S RNA (loading control).
Radioactive probed membranes were quantified by phos-
hoimager analysis using the Image Quant TL software
(GE Healthcare, Freiburg, Germany).
Western blot analysis
One-million HeLa cells were transduced for 3 h with
40 ml concentrated integrating (RSF91.cSB.PRE, RSF91
.SB100X.PRE or RSF91.SB100Xo.PRE) or RMT
(RSF91aPBS.cSB.PRE, RSF91aPBS.SB100X.PRE or
RSF91aPBS.SB100Xo.PRE) vector particles. Three
hours, 22 h and 12 days post-transduction cells were har-
vested, washed twice with phosphate-buffered saline and
cell lysates were obtained by using radioimmunopre-
cipitation assay buffer supplemented with proteinase in-
hibitors (Complete Mini; Roche, Mannheim, Germany).
Samples (25mg) were separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (12.5%), trans-
ferred to nitrocellulose membranes (Bio-Rad, Munich,
Germany), and probed with rabbit polyclonal anti-SB
transposase (19), goat anti-RLV p30 serum (kindly
provided by S.K. Ruscetti, National Cancer Institute at
Frederick, Frederick, MD) and mouse anti-a-Tubulin
(Sigma Aldrich) in Tris-buffered saline with 0.05% Tween
(Carl Roth GmbH, Karlsruhe, Germany) and 3% milk
powder (Carl Roth GmbH). Fluorophore-conjugated
IRDye 700
TM
DX anti-mouse IgG (ROCKLAND
Immunochemicals, Gilbertsville, PA), IRDye

800CW anti-
rabbit IgG (ROCKLAND Immunochemicals) and IRDye
680 donkey anti-goat IgG (LI-COR Biosciences, Bad
Homburg, Germany) served as secondary antibodies.
Detection and quantification was carried out by using
the Odyssey infrared imaging system (LI-COR
Biosciences).
Real-time PCR quantification
As for western blotting 1-million HeLa cells were trans-
duced for 3 h with RSF91aPBS.cSB.PRE, RSF91aPBS
.SB100X.PRE, RSF91aPBS.SB100Xo.PRE or the corres-
ponding integrating vectors. For real-time RT–PCR, the
total RNA of the transduced cells was prepared 3 and 22 h
post-transduction using the RNAzol extraction method
(WAK, Chemicals), liberated from plasmid and genomic
DNA and reverse transcribed as previously described (7).
For the determination of proviral vector copies, cells were
kept in culture and their genomic DNA was extracted at
Day 15 post-transduction with the QIAamp DNA blood
Mini Kit (Qiagen, Hilden, Germany). Quantitative PCRs
were performed on an Applied Biosystems StepOnePlus
Real-Time PCR System (Foster City, CA, USA) using
the Quantitect Sybr green reagent (Qiagen). The vector’s
PRE element was detected with oligonucleotide primers
50-GAGGAGTTGTGGCCCGTTGT-30 and 50-TGACA
GGTGGTGGCAATGCC-30 and normalized either to
the signal obtained by the amplification of human beta-
actin cDNA with primers 50-CCTCCCTGGAGAAGAG
CTA-30 and 50-TCCATGCCCAGGAAGGAAG-30
(RNA origin) or to the signal obtained by the amplifica-
tion of a conserved intron of the polypyrimidine tract-
binding protein 2 (PTB2) using primers 50-TCTCCATT
CCCTATGTTCATGC-30 and 50-GTTCCCGCAGAAT
GGTGAGGTG-30. All results were quantified using the
comparative threshold cycle method.
Apoptosis assays
The day before transduction, 2 105 HeLa or HeLa Fucci
cells were seeded and transduced with either 5 ml
concentrated supernatant of unidirectional integrating or
RMT vector particles or with integrating or
integrase-defective bidirectional vector particles at the
depicted MOIs. Cells were harvested either two (unidirec-
tional vectors) or four (bidirectional vectors) days
post-transduction, costained with propidium iodide and
APC-AnnexinV (BD Biosciences Clontech) according to
the manufacturer’s protocols and analyzed for apoptotic
cells via flow cytometry. Apoptosis was inhibited by
culturing the cells until analysis in the presence of 5 mM
Q-VD-OPH, a broad spectrum caspase inhibitor (MP
Biomedicals, Heidelberg, Germany).
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cH2AX immunofluorescence
The day before transduction, cover slips (12mm in diam-
eter, Carl Roth, Karlsruhe, Germany) were placed in wells
of a 12-well plate and 2 105 HeLa cells per well were
seeded on top. The next day, cells were transduced with
5 ml concentrated supernatant of RSF91.SB100Xo.PRE or
RSF91.FLPo.PRE and stained the following day for the
appearance of double strand breaks. In brief, cover
slips with cells were washed twice with phosphate-
buffered saline, fixed with 4% formaldehyde/phosphate-
buffered saline, permeabilized with 0.5% Triton
X-100/phosphate-buffered saline and stained with anti-
phospho-histone H2AX/Ser139 (clone JB301; Millipore,
Schwalbach, Germany). AlexaFluor488-conjugated goat
anti-mouse IgG (Invitrogen, Darmstadt, Germany)
served as secondary antibody. Cell nuclei were costained
with blue-fluorescent 40, 60-Diamidin-20-phenylindol
(DAPI) according the manufacture’s protocol (SelectFX
nuclear labelling kit for fixed cells, Invitrogen). One
hundred nuclei per sample were analyzed via fluorescent
microscopy for the occurrence of double strand break foci.
Phosphoplex analysis
Multiplex technology was used for determination of the
phosphorylation status of selected signaling proteins
(ERK1/2, p53, c-Jun and Akt) in cells that were trans-
duced with integrating iRV.SB100X or iRV.EGFP (both
RSF91+PRE) vectors. Four hundred thousand HeLa
cells were transduced with 5 ml of concentrated iRV
.SB100Xo or iRV.EGFP vector particles. At time points
24, 31, 46 and 54 h post-transduction cells were washed
twice with 1ml ice cold phosphate buffered saline (PAA)
and lysed within the culture plates. Cell lysis was carried
out using the Bio-Plex Cell Lysis Kit (Bio-Rad, Hercules,
USA) according to the manufacturer’s instructions. In
brief, 125 ml of cold lysis buffer was added per well, cells
were detached with cell scrapers and the resulting lysates
transferred into a 1.5ml reaction tube. Subsequently,
samples were gently rotated at 4C for at least 20min.
To further assist cell lysis, the samples were shock-frosted
at 80C, then thawed on ice and centrifuged at 17 000g
for 20–25min at 4C. The supernatants were stored at
20C until usage. Before subjecting the samples to
Phosphoplex analysis, total protein concentrations of all
cell lysates were determined with the Pierce BCA Protein
Assay Kit (Thermo Scientific, Bonn, Germany) and
adjusted to a concentration of 100 mg/ml and 50 ml of
each lysate were applied to the bead-based multiplex
analysis. Phosphoplex analysis was carried out according
the manufacturer’s protocol using the Bio-Plex machine
(Bio-Rad) with the Bio-Plex 6.0 software. Mean fluores-
cence intensity data of at least 50 beads for each total and
phosphorylated subset of proteins were collected and
applied to statistical analysis (±standard deviation of
the mean).
Statistical analysis
Data from the experiments are expressed as the means ±
standard deviations. The non-parametric Wilcoxon test
was used for comparison of differences between the indi-
cated groups. A P< 0.05 was considered significant.
RESULTS
Vector and protocol modifications to enhance the potency
of RMT
Initial experiments performed to deliver the cSB
transposase with first-generation RMT vectors (11) had
limited success. To elevate RMT titers and therefore the
expression of RNA vector genomes (gRNA) in retroviral
packaging cells, we first introduced Rous Sarcoma Virus
(RSV) enhancer/promoter sequences into the 50 long ter-
minal repeat (LTR) of RMT vector expression plasmids
(20). We also added the full-length 900 bp fragment of the
Woodchuck Hepatitis Virus post-transcriptional regula-
tory element (PRE) 30 of the SB cDNA, to enhance
mRNA processing and stability (Figure 1A) (21–23).
Furthermore, we codon-optimized the hyperactive
SB100X reading frame for enhanced initiation of transla-
tion [insertion of an optimized Kozak consensus sequence
(24)] and efficient codon-usage in human cells, simultan-
eously deleting cryptic splice and polyadenylation motifs.
The resulting optimized cDNA was named SB100Xo
(sequence alignment of SB100X and SB100Xo in
Supplementary Figure S1). As transposable elements, we
developed constructs expressing fluorescent proteins under
control of the ubiquitously active Spleen Focus-forming
Virus promoter (SFFV) (Figure 1B). RMT vector particles
pseudotyped with the Vesicular Stomatitis Virus glycopro-
tein (VSVg) were produced concentrated and used to
transduce HeLa cells. Twenty-two hours later, a transpos-
able element encoding EGFP (pSK.IR.SF.EGFP.pA.IR)
was cotransfected using polyethyleneimine (PEI) and the
transfection efficiencies were quantified by flow cytometry
2 and 21 days post-transfection. The efficiency of trans-
position was calculated by determining the ratio of cells
expressing the transposable elements at 21 days versus 2
days after delivery. Thus, a value of one reflects a trans-
position rate of 100%.
Individually and even more collectively, the modifica-
tions of the RMT vectors (Figure 1A) greatly enhanced
SB transposase expression levels in producer cells (spliced
and unspliced vector mRNA, Figure 1C; protein,
Supplementary Figure S2A; correlation of mRNA and
protein levels, Figure 1D). The improvements of the
vector backbone and the codon-optimization cooperated
to increase the potency of the RMT approach (Figure 1E
and F; Supplementary Figure S2B–D), leading to highly ef-
ficient transposition mediated by as little as 5ml of
50 concentrated RMT vector preparations (Figure 1F).
To illustrate the potency, a single vector production from
a 10-cm dish of producer cells provided RMT vectors in
quantities sufficient for 65 experiments (for 2 105 target
cells per experiment). Our approach also reproduced the
substantially increased potency of SB100X compared to
cSB [Supplementary Figure S2B–D, (2)]. Indeed, the
increased potency of SB100X was necessary to transfer
efficient transposase activity by RMT. When the transpos-
able element encoding EGFP (Figure 1B) was transfected
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Figure 1. SB transposase expression from new generation RMT vectors allows highly efficient transposition in HeLa cells. (A) Schema of RMT
vector plasmids. The original RMT vector is shown in its pUC-plasmid formation (pSF91aPBS, vector 1) and comprises the long terminal repeats
(LTR; U3, R, U5), the mutated artificial primer binding site (aPBS), splice donor (SD), retroviral packaging signal (c), splice acceptor (SA) and
either the conventional, the 100X hyperactive or a codon-optimized version of the 100X Sleeping Beauty (SB) transposase (cSB, SB100X and
SB100Xo, respectively). The 50 U3-enhancer-promoter is derived from the Myeloproliferative Sarcoma Virus (MPSV) and the 30 U3 region from the
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into HeLa cells 22 h after RMT of SB100X or SB100Xo,
transposition rates reached up to 100% (Figure 1F and
Supplementary Figure S2D).
Since the potency of RMT supernatants is dependent on
the viral genomic RNA (gRNA) rather than the viral
capsid (p30) content (7), we determined for a subset
of RMT vector stocks (RSF91aPBS.cSB.PRE,
RSF91aPBS.SB100X.PRE and RSF91aPBS.SB100Xo.
PRE), the viral gRNA load in comparison to correspond-
ing RSF91.EGFP.PRE vector preparations. Vector stocks
were produced and concentrated under identical condi-
tions, extensively DNase treated and subjected to
real-time RT–PCR analysis (Supplementary Figure S2E).
On HeLa cells, RSF91.EGFP.PRE preparations had a
functional titer of 1 109 transducing units/ml (data
not shown). As already indicated by the
RSF91aPBS+PRE vector signal in northern blot
analysis of transfected producer cells (Figure 1C), we
found that modifications of the SB reading frame (cSB,
SB100X and SB100Xo) had no impact on the titer of
RMT particle preparations. For practical reasons, we per-
formed further studies with RMT vector doses determined
by volume.
To accurately determine the impact of codon-
optimization, we coexpressed SB100X or its codon-
optimized variant, SB100Xo, in combination with EGFP
from bidirectional gammaretroviral (RBid) and lentiviral
(LBid) vectors (Supplementary Figure S3A) allowing the
identification of SB expressing cells by EGFP fluorescence
(18). The vector particles were generated using a gag/pol
expression construct harboring a point mutation in the
catalytic core domain of the viral integrase, thereby pro-
moting the establishment of extrachromosomal episomal
proviral DNA (14). HeLa cells transduced with
integration-defective vectors (episomal vectors eLBid
and eRBid) of known titer, produced comparable trans-
duction rates. Twenty-two hours post-transduction a
transposable element plasmid expressing mCherry
(pSK.IR.SF.mCherry.pA.IR, Figure 1B) was transfected
and the cells were analyzed via flow cytometry 2 and 14
days post-transfection. Calculation of the transposition
rates (ratio of mCherry+ cells at Day 14 and EGFP+/
mCherry+ cells at Day 2) revealed an up to 3-fold better
performance of SB100Xo in comparison with SB100X
(Supplementary Figure S3B and C). The significantly
increased potency of SB100Xo was also documented by
RMT with vectors SF91aPBS and RSF91aPBS
(Supplementary Figure S2B and C), but undetectable
under the saturating expression conditions achieved with
the most potent RMT vector, RSF91aPBS+PRE
(Supplementary Figure S2D). These experiments
revealed that transcriptional and post-transcriptional
modifications of the SB expression vector increased the
potency to an extent that allowed highly efficient trans-
position by mRNA delivery.
Using the best-performing vector setting
(RSF91aPBS+PRE), we tested whether cotransduction
of HeLa cells with RMT of SB100Xo and integration-
defective episomal lentiviral vectors delivering the trans-
posable element (eLVTE, Figure 2A) mediates efficient
transposition. Such an experimental setup is of interest
for cells that are refractory or oversensitive to physico-
chemical transfection. Interestingly, combining RMT of
SB100Xo and eLVTE resulted in higher transposition
rates when compared to settings where SB100Xo was
provided by episomal gammaretroviral or lentiviral bidir-
ectional vectors (14% versus 7 and 4%, respectively,
Figure 2B) Our results compare favorably with two
recent publications which explored combinatorial eLV
for transposition (25,26). In primary MEFs derived from
CF1 mice, we achieved similar rates using RMT, although
epigenetic silencing of the transposable element
complicated the analysis in these cells (Supplementary
Figure S4). The more rapid onset and possibly also the
shorter duration and lower level of transposase expression
may have accounted for the improved potency of RMT
compared to eLV.
Efficient transient delivery of FLP recombinase into
various cell types
To further explore the potential of the improved RMT
vectors, we replaced SB by the codon-optimized FLPo
(15), produced particles as above, and transduced
HT1080 indicator cells harboring two lentivirally trans-
duced copies of a reporter gene in which FLP-mediated
excision of EGFP induces expression of dTomato
(Supplementary Figure S5A and B). The conversion of
green to red fluorescence is a reliable indicator of FLP
Figure 1. Continued
Spleen Focus Forming Virus (SFFV). To improve RMT, the 50 MPSV promoter was replaced by the Rous Sarcoma Virus (RSV) U3 (pRSF91aPBS,
vector 2). To further enhance SB expression levels, the 900 bp fragment of the Woodchuck Hepatitis Virus post-transcriptional-regulatory element
(PRE) containing polyadenylation enhancer sequences was inserted (pRSF91aPBS+PRE, vector 3). (B) Bluescript plasmids (pSK) harboring the
transposable elements (TE) were used in this study. SFFV driven expression cassettes encoding either for EGFP (pSK.IR.SF.EGFP.pA.IR) or the
red fluorescent mCherry (pSK.IR.SF.mCherry.pA.IR) protein are flanked by the so-called inverted and directed repeats (IR and DR, respectively),
the recognition sites of the SB transposase. The resulting transcripts are terminated by the introduction of the SV40 polyadenylation signal (pA). (C)
Northern blot analysis of transfected 293T cells. All three types of SB variants (cSB, SB100X and SB100Xo) were tested in each vector setting:
pSF91aPBS (1), pRSF91aPBS (2) and pRSF91aPBS+PRE (3). RNA was harvested 36 h post-transfection and probed against the 30 SFFV U3
region. 18S RNA served as a loading control. The upper band of each lane corresponds to the unspliced RNA and the lower band reflects the spliced
species. (D) Correlation of relative RNA and protein levels of SB100X and SB100Xo constructs. Levels of pSF91aPBS.SB100X (SB100X vector 1)
were set to 100%. (E) Efficient RMT mediated SB transposition in HeLa cells. The HeLa cells were first transduced with 5 ml SF91aPBS or
RSF91aPBS or RSF91aPBS+PRE SB100Xo particles and then transfected 22 h later with a plasmid harboring the transposable element
encoding for EGFP. FACS plots of cells analyzed 2 and 21 days post-transfection are depicted. Cells only transfected (Trf.) with the transposable
element served as control. (F) Summary of three independent experiments with increasing levels of viral supernatants as used in (E).
RSF91aPBS.SB100Xo.PRE supernatants generated without (w/o) Gag/Pol served as control for protein or plasmid carry-over from the packaging
cell. The light gray shaded area indicates mean background plasmid integration levels of the transposable element.
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activity in these cells (17). Very similar to the data
obtained with SB, the modification of the promoter and
the insertion of the PRE synergistically increased FLPo
delivery, leading to a 50-fold increased potency of both,
RMT and iRV (Figure 3A and B). Titration experiments
revealed that a 25-fold higher volume of vector super-
natant was needed for RMT in comparison to iRV. This
is remarkable, as each retroviral particle contains only two
copies of the plus-stranded mRNA genome. Furthermore,
we tested FLPo delivery by episomal gammaretroviral and
lentiviral bidirectional vectors (eRBid.FLPo, eLBid
.FLPo) and found these to mediate efficient and reprodu-
cible recombination of SC-1 based cells carrying one FLP
reporter allele (Figure 3C–E and Supplementary Figure
S5B). Next, we investigated the potency of RMT to
deliver FLPo by transducing SC-1 fibroblasts or murine
IPS, both containing the FLP reporter. An integrating
gammaretroviral vector encoding FLPo served as
positive control. With a strictly dose-dependent perform-
ance, RMT reached a high efficiency: we obtained >95%
recombined SC-1 fibroblasts (Supplementary Figure S5C)
and 40% recombined iPS cells (MOI 40, Figure 3F).
Thus, RMT efficiently delivers different types of DNA-
modifying enzymes (SB transposase and FLP recombin-
ase) into various cell types.
Dose-dependent cytotoxicity of SB transposase
In the course of all experiments, integrating gammaretro-
viral and lentiviral vectors (uni- or bidirectional)
expressing cSB, SB100X, SB100Xo or FLPo served as
positive controls. However, in cultured cells stably
transduced by these vectors, we observed pronounced
cytotoxicity with either of the SB variants. Cytotoxicity
was accompanied by low transposition rates
(Supplementary Figure S6A and B) due to increased cell
death occurring within a few days after transduction
(Supplementary Figure S6C and D). Cytotoxicity only
depended upon the delivery of the transposase, and
occurred in the absence of a co-delivered transposable
element. As SB is not known to recognize endogenous
transposable elements of the human genome (27)
continued transposition was an unlikely explanation for
the observed toxicity.
To further examine the cytotoxic effects, we used the
most potent integrating or RMT vector setting to trans-
duce HeLa cells and monitored the corresponding
SB protein expression levels 3 and 22h as well as 12 days
after transduction (Figure 4A). To ensure equal particle
load, all cells were additionally analyzed for retroviral
capsid protein (p30) and retroviral genomic mRNA levels
at early (3 h) and late (p30: 22 h and 12 day; genomic
mRNA: 22 h) time points (Figure 4A and B). Whereas
SB expression was barely visible in all cell lysates harvested
3h post-transduction, it was clearly detectable in cells,
transduced by iRV or RMT particles, 22h after transduction
(Figure 4A). However, SB expression from iRV vectors
decreased over time (12day), correlating with decreased
levels of proviral genomic DNA (Figure 4A and C). These
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Figure 2. Cotransduction of RMT.SB100Xo and episomal lentiviral vector particles delivering the transposable element results in efficient trans-
position in HeLa cells. (A) Lentiviral self inactivating (SIN, U3) vector backbone harboring the transposable element (TE) expression cassette as
shown in Figure 1B. RRE, rev responsive element; , packiging signal. To obtain integration-defective episomal lentiviral TE particles (eLVTE), the
vector was packaged with a Gag/Pol mutant harboring the D64V mutation within the core domain of the viral integrase. (B) HeLa cells were
cotransduced with 10 ml concentrated eLVTE (MOI 3.5) and 30 ml concentrated RMT.SB100Xo (RSF91+PRE), or unconcentrated episomal bidir-
ectional lentiviral or retroviral SB100Xo (eLBid.SB100Xo, eRBid.SB100Xo; both MOI 0.3) particles. Cells were analyzed via flow cytometry 3 and
15 days post-transduction. Cells that were only transduced with eLVTE or eLBid.SB100Xo or eRBid.SB100Xo served as controls for background
integration events.
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Figure 3. Optimization of the retroviral integrating and RMT vector backbones enhances FLPo-mediated recombination. (A and B) Human
HT1080-derived FLP indicator cells harboring two lentivirally transduced copies of a FLP reporter gene [with conversion of EGFP to dTomato
expression after FLP exposure, (17)] were transduced with integrating retroviral (iRV) or RMT particles encoding for codon-optimized FLPo
expressed from different vector backbones (see also Figure 1A). The graphs display the percentage of recombined cells in relation to the amount
of non-concentrated supernatant used. (C) Schematic overview of episomal bidirectional lentiviral and gammaretroviral SIN vectors coexpressing
FLPo and EGFP (eLBid.FLPo, eRBid.FLPo). Both vectors consist of two independent transcription units: SFFV promoter driven FLPo is expressed
in sense and terminated at the viral’s polyadenylation signal (pA) located within R of the 30LTR. EGFP is cloned in antisense orientation to the
vector backbone and is expressed by a minimal CMV (mCMV) promoter that is trans-activated by SFFV. The EGFP antisense transcript is
terminated by the SV40 polyadenylation signal (pA). To facilitate nuclear export the constitutive transport element (CTE) of Mason-Pfizer
Monkey Virus was inserted. PRE*: 600 bp post-transcriptional element of the Woodchuck Hepatitis Virus, devoid of the X open reading frame
(18). (D and E) Efficient FLPo transfer using eLBid.FLPo and eRBid.FLPo particles. Murine SC-1-based FLP indicator cells harboring one copy of
the FLP reporter allele were transduced with increasing MOIs as depicted and analyzed via flow cytometry for recombination efficiencies (E).
Representative FACS plots of transduced cells (MOI 1) 36 h and 16 days post-transduction (D). (F) Efficient transient FLPo transfer into murine
induced pluripotent stem cells (mIPS). RMT.FLPo and iRV.FLPo particles were titrated on murine FLP indicator cells (see also Supplementary
Figure S5) and the percentage of recombined cells was used for titer determination. Murine IPS cells harboring the FLP indicator expression cassette
were transduced with both particle types at an MOI of 40. Non-recombined EGFP expressing cells are shown on the x-axis and recombined
dTomato expressing cells on the y-axis.
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data suggested that persistent SB expression is cytotoxic
and may lead to cell death.
Interestingly, when transducing cells with iRV, expres-
sion levels of SB and persistence of cells expressing SB
were inversely correlated with the potency of the
transposase variant (Figure 4A–C). In contrast, RMT
led to a transient expression of SB, declining rapidly
between 3 and 22 h (Figure 4B), and disappearing traceless
in long-term cultivated cells at the level of both nucleic
acid and protein (Figure 4A and C), without evidence for
toxicity.
Cell death occurred in p53-low HeLa cells (28) and CF1
MEFs, where mortality increased up to 20% by Day 2 or
11 post-transduction, respectively and cell growth ceased
in the surviving cells (Supplementary Figure S6C–F).
Whereas cytotoxicity was observed with constitutive ex-
pression of SB100Xo, SB100X and cSB, continued expres-
sion of FLPo was only slightly more toxic than mock
treatment (Supplementary Figure S6E). AnnexinV/
propidium iodide (PI) costaining 2 days post-transduction
indicated that SB-mediated cell loss was mainly caused by
apoptosis (Figure 5A and Supplementary Figure S6E),
whereas the proportion of AnnexinV+ cells was minor in
cells transduced with the same bidirectional retroviral ex-
pression constructs encoding FLPo or a truncated version
of the CD34 receptor [tCD34, (29)] (Supplementary
Figure S7A and B). Interestingly, even transient expres-
sion of SB100X or SB100Xo from episomal bidirectional
vectors induced apoptosis, which was dependent on the
dose of the transposase (Supplementary Figure S7C).
This toxicity may have contributed to the reduced
potency of eLV compared to RMT for delivery of SB,
as indicated in the above experiments (Figure 2).
SB-mediated cytotoxicity is preceded by a G2/M cell
cycle arrest
When transducing HeLa Fucci cells that allow the moni-
toring of cell cycle stages by expressing monomeric
versions of the fluorescent proteins Kusabira Orange
(mKO2) and Azami Green [mAG, Figure 5B; (16)] a
pronounced pre-mitotic cell cycle arrest in the S/G2/M
cell fraction became apparent 2–3 days post-transduction
(upper left quadrants in Figure 5C). A new population
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Figure 4. RMT-mediated SB expression is transient and non-toxic. (A) Western blot analysis of transduced HeLa cells. Choosing the most potent
vector backbones (RSF91aPBS+PRE or RSF91+PRE), HeLa cells were transduced with RMT and integrating retroviral vector (iRV) particles
encoding either for cSB, SB100X or SB100Xo. Cell lysates were prepared 3 h, 22 h and 12 days post-transduction and analyzed for SB transposase
and retroviral capsid (p30) expression levels. a-Tubulin protein expression levels served as loading control. Relative p30 levels (%) in cells that were
harvested 3 h post-transduction are indicated. They were determined and normalized to a-tubulin expression levels. RSF91.cSB.PRE was set to
100%. (B) Retroviral vector RNA levels early (3 h) and late (22 h) after cellular entry. Total RNA was harvested from cells shown in (A) and
analyzed via real-time RT-PCR for relative vector mRNA levels 3 and 22 h post-transduction (value for iRV.cSB was set to one). The value for RMT
of cSB was not determined (n.d.). (C) Detection of proviral vector DNA via quantitative PCR. To rule out plasmid contamination, genomic DNA
was harvested 15 days post-transduction and analyzed by qPCR using primers directed against the PRE. The graph depicts relative vector levels. The
value for iRV.cSB was set to 100%.
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Figure 5. Constitutive expression of SB transposase is cytotoxic. (A) HeLa cells were transduced with iRV and RMT vectors (RSF91+PRE or
RSF91aPBS+PRE) encoding either for codon-optimized FLPo, cSB, SB100X and codon-optimized SB100Xo. Two days post-transduction cells were
stained for early apoptotic and late apoptotic/dead cells using propidium iodide and AnnexinV staining and analyzed via flow cytometry. (B) Typical
FACS plot of HeLa Fucci cells (16). Due to the cell cycle-dependent inverse oscillation of both fusion proteins (orange mKO2-hCdt1 and green
mAG-hGeminin), the nuclei of HeLa Fucci cells being within G1 are labelled in red, whereas nuclei in S/G2/M phases are represented by green
fluorescence. The transition of G1/S results in mKO2-hCdt1 and mAG-hGeminin double positive nuclei and the transition of M/G1 is indicated by
unstained nuclei. (C) Constitutive SB100Xo expression leads to a G2/M arrest. HeLa Fucci cells were transduced with integrating iRV.FLPo,
iRV.SB100Xo or RMT particles encoding for SB100Xo (all RSF91+PRE). One to three days post-transduction cells were analyzed via flow
cytometry. (D) The additional population observed in (C) represents apoptotic (AnnexinV+) cells. HeLa Fucci cells were transduced with integrating
iRV.SB100Xo and analyzed on Day 3 after transduction. (E) Summary of 2–3 independent experiments showing the premitotic arrest in cells
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with weak expression of the endogenous cell cycle marker,
Geminin-mAG, was observed in cells transduced with
SB100Xo vectors three days post-transduction (located
toward the bottom of the upper left quadrants in
Figure 5C), and this population was AnnexinV+ (Figure
5D). Quantification of the flow cytometry plots showed
that transduction with iRV expressing SB100Xo doubled
the proportion of cells in S/G2/M compared to controls
(iRV expressing FLPo or RMT of either SB100Xo or
FLPo), already at Day 2 post-transduction (Figure 5E).
When encoding FLPo, RMT avoided the induction of
a relatively mild pre-mitotic arrest that was detectable
on Day 3 when using integrating expression vectors
(Figure 5E).
Since Geminin is one of the direct substrates of the cell
cycle regulating ubiquitin–protein ligase
anaphase-promoting-complex, which is mainly active in
mitosis and the G1 phase of the cell cycle (16), the accu-
mulation of single positive Geminin-mAG cells strongly
suggests that prolonged and high-level expression of the
transposase perturbs the progression from G2 into mitosis
(Figure 5C). Our data thus reveal a dose-dependent G2/M
cell cycle arrest and induction of apoptosis caused by the
overexpressed transposase. In addition, these experiments
demonstrate the utility of Fucci cells (16) to indicate both,
alterations of cell cycle progression caused by an
overexpressed DNA modifying enzyme and apoptotic
cell populations.
SB-mediated cytotoxicity does not depend on its catalytic
activity and can be prevented using caspase inhibitors
Pre-mitotic cell cycle arrest can be indicative of enhanced
DNA repair. We thus performed gH2AX stains, but
found only moderately increased numbers of DNA
repair foci after expressing SB from integrating vectors,
whereas FLPo had no significant effect (Figure 5F). In
order to better understand the apoptotic fate of cells
transduced with SB, we additionally performed multiplex
phosphoprotein expression analyses for a subset of signal-
ing molecules that are key regulators of cellular stress re-
sponses. We thus found a highly significant induction of
p53 and c-Jun (both total protein and phosphorylated
forms), a trend to reduced total ERK1/2 protein levels,
although phospho-ERK1/2 variants were increased at
later time points (Figure 6D–F), and, always compared
to the EGFP control, no major effect of SB100X on
Akt, a marker of endoplasmic reticulum (ER) stress (30)
(Supplementary Figure S8).
To explore whether cytotoxic effects of SB overexpres-
sion depended on its catalytic domain, we introduced and
validated triple mutations of the DDE motif that is essen-
tial for the DNA-cleavage activity of the transposase
(Figure 6A). As cell cycle arrest and apoptosis were only
slightly reduced compared to the enzymatically active
SB100X, our data suggest that DNA cleavage is not the
primary mechanism of cell cycle arrest and apoptosis
(Figure 6B and C).
These results prompted us to analyze whether
transposase-dependent cytotoxicity also occurs upon con-
ventional transfection to deliver cSB, SB100X and
SB100Xo, using the improved plasmids designed for gen-
eration of RMT particles (pRSF91aPBS+PRE, Figure
1A) or a standard expression vector [pCMV.SB100X,
(2)]. Again, we observed an increase of apoptosis and
cell death, which was reproducibly higher than the back-
ground toxicity of the transfection method
(Supplementary Figure S9). Importantly, when using
pRSF91aPBS.SB100X.PRE at the lowest plasmid dose
required for efficient transposition (10 ng per well), cyto-
toxicity of SB100X was not exceeding the background
toxicity of the transfection procedure. Finally, we were
able to dissect SB’s induction of cell cycle arrest and apop-
tosis by irreversibly inhibiting the caspase pathway using
Q-VD-OPH (31), further indicating that apoptosis occurs
as a consequence of the G2/M arrest (Figure 6G). Thus, in
sum, transient and dose-controlled delivery of SB by RMT
avoided cytotoxic effects (Figure 5 and Supplementary
Figure S6), while mediating efficient integration of trans-
posable elements delivered via either physicochemical
transfection or episomal lentiviral vectors (Figures 1 and
2; Supplementary Figure S2 and S4).
DISCUSSION
The present study introduces an improved retroviral
particle-mediated platform for efficient mRNA delivery
of DNA-modifying enzymes such as the SB transposase
or the FLP recombinase. Using a previous, less-efficient
generation of RMT vectors, delivery of the Cre recombin-
ase has been demonstrated (11). The efficiency of RMT
correlates with the amount of retroviral mRNA genomes
in viral particles (7). In the present study, we increased the
potency of RMT by vector modifications that enhance the
generation of vector mRNA in producer cells. We
codon-optimized the SB100X cDNA and introduced the
longest version of the Woodchuck Hepatitis Virus PRE
(20,23), which among all PREs tested by us to date has
the greatest effect on post-transcriptional mRNA process-
ing, including transcriptional termination,
polyadenylation and translation (21,22). The rationale
for the long PRE and the codon-optimization of
SB100X was not only to maximize RNA expression in
packaging cells but also to enhance the efficiency of trans-
lation in target cells. Since expression levels are not a
major limitation for DNA transfection-based delivery of
Figure 5. Continued
constitutively expressing SB100Xo. As additional control RMT.FLPo particles were included. (F) HeLa cells constitutively expressing SB100Xo show
an increase in double strand breaks compared to Mock or FLPo expressing cells. Cells were analyzed 1 day post-transduction using the gH2AX
immunofluorescence assay. For iRV.SB100Xo (RSF91+PRE) three independent experiments were performed counting the foci of 100 nuclei each,
for iRV.FLPo (RSF91+PRE) 2 100 nuclei and for Mock 1 100 nuclei were analyzed.
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SB, these modifications are of special interest for mRNA
transduction methods.
At first glance, it may appear ironic to deliver a
transposase, designed as a nonviral alternative of an
integrating vector, in the form of mRNA released from
RT-deficient retroviral particles. However, as
demonstrated in this study, the RMT approach
introduced a potent, well-tolerated and non-cytotoxic
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Figure 6. Analysis of cellular effects of SB100X overexpression. (A) Inactivation of the SB’s catalytic domain by mutating the DDE motif completely
inhibits transposition. To avoid excessive cytotoxicity HeLa cells were transduced with just 1 ml (instead of 5 ml) concentrated wild-type iRV.SB100X
or mutant iRV.mutSB100X. The following day the transposable element plasmid pSK.IR.SF.EGFP.pA.IR was cotransfected. Cells were FACS
analyzed for EGFP expression 2 and 23 days post-transfection and the resultant transposition rates were determined. Cells that were transfected in
the absence of SB100X served as control for residual integration events of the transposable element plasmid (Trf. Control). (B and C) DDE mutated
SB100X just slightly reduces cytotoxicity. HeLa Fucci cells were transduced with 5 or 10 ml concentrated iRV.SB100X or the corresponding DDE
motif mutant. Two days post-transduction cells were stained with AnnexinV and analyzed for the percentage of cells being either within S/G2/M (A)
or AnnexinV positive (B). Except for untreated cells (Mock, N=2) three independent experiments are shown, respectively. (D–F) Overexpression of
SB transposase leads to enhanced phosphorylation of p53, c-Jun and ERK1/2 in HeLa cells. HeLa cells were transduced with four different
preparations integrating iRV.SB100X (RSF91+PRE, dark gray bars) or two preparations of corresponding integrating iRV.EGFP supernatants
(light gray bars). Untreated HeLa cells served as mock control (white bar). Cells were lysed within culture plates at the indicated time points and
subjected to phosphoplex analysis. Four different signaling molecules (p53, c-Jun, ERK1/2 and Akt) have been analyzed for total and phospho-
protein levels, however only the phosphorylation status of p53 (D), c-Jun (E) and ERK1/2 (E) are shown. The corresponding total protein levels as
well as total and phosphoprotein levels of Akt are depicted in Supplementary Figure S8. Error bars reflect the standard deviation of the MFI of >50
events. (G) The G2/M arrest induced by SB overexpression is independent from apoptosis. HeLa Fucci cells were transduced with 5 ml concentrated
iRV.SB100X in the presence or absence of the caspase inhibitor Q-VD-OPH (5mM). Two days post-transduction the percentage of cells in S/G2/M
or those being AnnexinV positive were determined. The error bars show the standard deviation of the mean of two independent experiments.
7158 Nucleic Acids Research, 2011, Vol. 39, No. 16
platform for dose-controlled and short-lasting expression
of the SB transposase. Importantly, we found that pro-
longed, high-level expression of the transposase from
episomal or integrating vectors not only resulted in
reduced cell growth, but also triggered apoptosis in a
dose-dependent manner. The considerable cytotoxicity of
physicochemical transfection methods, previously used by
most investigators to deliver transposases as plasmids or
in the form of purified mRNA, may have masked toxic
effects of overexpressed transposase.
Our detailed studies, using the recently introduced
HeLa Fucci cells which allow color-coded cell cycle
analyses (16), surprisingly revealed that apoptosis
induced by SB overexpression is preceded by a substantial
G2/M arrest. Irreversible inhibition of the caspase
pathways by Q-VD-OPH further supported that apoptosis
is secondary to the pre-mitotic cell cycle arrest. In
addition, we observed substantial induction of p53 and
c-Jun as well as increased numbers of gH2AX foci.
Phosphorylation of p53 at serine 15 and c-Jun at serine
63 are signaling events that indicate DNA damage and/or
other forms of cellular stress (32,33). Our results might
indicate that the observed cytotoxicity is a consequence
of double-strand breaks induced by off-target cleavage
events mediated by SB. However, gH2AX foci in cells
overexpressing SB were only moderate when compared
to untreated cells and despite the generally accepted
view of gH2AX being a marker of double strand break
repair, DNA damage-independent functions of gH2AX
have been suggested (34). Furthermore, inactivation of
SB’s catalytic domain (triple mutant of DDE motif) only
slightly reduced cytotoxicity, further arguing against un-
directed DNA cleavage by SB in the absence of the trans-
posable element. Notably, the G2/M arrest may not
always be triggered by DNA damage and can be also
induced by other pathways inducing p53 (35–37). The
phosphoprotein signature of Akt gave no evidence for
ER stress-induced apoptosis mediated by potentially
unfolded or misfolded proteins. However, SB overproduc-
tion may also induce other forms of misfolded protein
responses in the cytosol or nucleus (38) or interfere with
cell cycle progression by other mechanisms not involving
its catalytic domain. Therefore, the exact mechanism of
cell cycle arrest and apoptosis induced by SB
overexpression remains to be defined. It is reassuring to
note that the ectopic expression of the SB transposase was
not found to be sufficient to cause developmental defects
or cancer in experimental animals (39). Furthermore, our
data indicate that cell stress induced by SB overexpression
is likely to be self-limiting due to the induction of cell
death with elimination of affected cells from a polyclonal
cell pool.
By reducing the level and duration of transposase ex-
pression, RMT and dose-adapted transfection could
prevent toxicity and should also reduce the rate of second-
ary transposition events, which may be caused by excision
and re-integration of the transposon (40). Importantly, we
demonstrate that SB-dependent cytotoxicity can be
avoided without compromising efficacy, a finding that is
likely to be similarly relevant for other methods of
transposase delivery and other types of transposons. The
RMT platform should also be applicable to other
transposases [such as PiggyBac (41) or Frog Prince (42)].
Furthermore, RMT was also found to efficiently trans-
duce the FLP recombinase, again avoiding residual toxic
effects that could be detected in our sensitive assay
systems.
Other approaches for transient and dose-controlled
delivery of DNA-modifying enzymes may rely on
mRNA transfection, membrane-permeable proteins (43)
or virus-like particles (17). The latter shares an important
conceptual advantage with RMT: as shown in previous
studies (11,17), retrovirus particle-mediated delivery of
mRNA or protein can be confined to specific cell types
by the choice of the viral envelope protein. Taking advan-
tage of novel pseudotyping strategies (44), an increasing
variety of cell types may be targeted. As exemplified with
SB and FLPo, the here introduced optimized RMT
vectors represent an efficient platform for transient cell
manipulation, and are of special interest for approaches
that benefit from a transient expression of proteins for
genome modification.
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